HIV drug exposure in womb may alter baby's immune diversity
NCT ID NCT04024150
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This study checked whether HIV drugs called anti-integrases, taken during pregnancy, affect a newborn's immune system. Researchers compared 29 full-term babies exposed to these drugs in the womb with those exposed to other HIV drugs. A single blood sample at birth measured T-cell diversity, a key part of immune health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-INTEGRASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP, Hôpital Bichat-Claude Bernard
Paris, 75018, France
-
AP-HP, Hôpital Cochin
Paris, 75014, France
-
AP-HP, Hôpital Louis Mourier
Colombes, 92700, France
-
AP-HP, Hôpital Necker
Paris, 75015, France
-
AP-HP, Hôpital de la Pitié Salpêtrière
Paris, 75013, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
raltegravir, elvitegravir, dolutegravir, or bictegravir (anti-integrase HIV drugs)
What this could lead to
If successful, this could help doctors understand whether certain HIV drugs are safer for the baby's developing immune system during pregnancy.
What could go wrong
This is a small, completed observational study with only 29 newborns, so results may not apply broadly. It looks at immune markers at birth, not long-term health outcomes.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.